#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12798	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2032	620.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1411	1411	C	697	C,A	671,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	12798	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2032	620.0	0	HET	.	.	.	C519T,A	.	519	519	C	746	746	C	760	C,T,A	564,175,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23780	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3529	669.0	0	.	n	.	0	T695C	SNP	695	695	T	1028	1028	C	703	C,T	689,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23780	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3529	669.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1670	1670	A	780	A,G	764,4	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23780	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3529	669.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2304	2304	C	724	C	700	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23780	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3529	669.0	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2930	2930	T	706	T,C	679,13	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23780	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3529	669.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2378	2378	A	755	A,G	733,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23780	23S	2890	2890	99.86	23S.l6.c4.ctg.1	3529	669.0	0	HET	.	.	.	G540A	.	540	540	G	873	873	G	760	G,A	401,329	.	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1734	folP	852	852	100.0	folP.l6.c30.ctg.1	1836	93.7	1	SNP	p	R228S	1	.	.	682	684	AGC	1260	1262	AGC	167;166;166	A;G;C	164;161;163	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4574	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3459	131.3	1	SNP	p	S91F	0	.	.	271	273	TCC	706	708	TCC	129;128;130	T;C;C	126;126;126	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4574	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3459	131.3	1	SNP	p	D95N	0	.	.	283	285	GAC	718	720	GAC	128;132;131	G;A;C	125;129;128	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4574	gyrA	2751	2751	99.85	gyrA.l15.c17.ctg.1	3459	131.3	1	SNP	p	D95G	0	.	.	283	285	GAC	718	720	GAC	128;132;131	G;A;C	125;129;128	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1354	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1287	104.1	0	.	p	.	0	A39T	NONSYN	115	117	GCC	407	409	ACC	173;173;173	A,G,C;C;C	158,2,1;168;166	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1354	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1287	104.1	0	.	p	.	0	R44H	NONSYN	130	132	CGC	422	424	CAC	165;164;163	C;A,G;C	163;157,1;160	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1354	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1287	104.1	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	605	607	CAC	195;195;196	C,T;A;C	186,2;184;188	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1354	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1287	104.1	1	SNP	p	G45D	0	.	.	133	135	GGC	425	427	GGC	159;157;155	G,T;G;C	153,1;156;152	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	834	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	988	83.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4190	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2971	140.3	1	SNP	p	D86N	0	.	.	256	258	GAC	538	540	GAC	171;170;168	G;A;C	168;166;165	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4190	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2971	140.3	1	SNP	p	S87R	0	.	.	259	261	AGT	541	543	AGT	170;172;172	A,C;G;T	163,3;170;169	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4190	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2971	140.3	1	SNP	p	S87W	0	.	.	259	261	AGT	541	543	AGT	170;172;172	A,C;G;T	163,3;170;169	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4190	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2971	140.3	1	SNP	p	S87I	0	.	.	259	261	AGT	541	543	AGT	170;172;172	A,C;G;T	163,3;170;169	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4190	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2971	140.3	1	SNP	p	S88P	0	.	.	262	264	TCC	544	546	TCC	172;172;169	T;C;C	168;169;167	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3470	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2608	132.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1552	1554	GGC	179;177;178	G;G;C	176;174;168	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	A311V	0	.	.	931	933	GCA	1190	1192	GCA	210;211;212	G;C;A,C	204;201;206,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	I312M	0	.	.	934	936	ATC	1193	1195	ATC	212;211;217	A;T;C,A,G	209;204;208,2,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	V316T	0	.	.	946	948	GTG	1205	1207	GTG	211;207;208	G,A;T,C;G,C	202,1;198,1;201,1	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	V316P	0	.	.	946	948	GTG	1205	1207	GTG	211;207;208	G,A;T,C;G,C	202,1;198,1;201,1	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1709	1711	ACC	138;135;135	A;C;C	128;130;130	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1763	1765	GCG	124;125;124	G;C,G;G	121;113,2;122	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1763	1765	GCG	124;125;124	G;C,G;G	121;113,2;122	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1886	1888	GGC	127;124;122	G;G;C,A	120;119;119,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1895	1897	GGC	111;106;105	G;G;C	109;103;104	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3282	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2286	142.1	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1913	1915	CCG	88;88;90	C,G;C,G;G,C	77,1;77,1;75,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4820	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3172	150.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2212	porA	1146	1146	99.83	porA.l6.c30.ctg.1	1992	110.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	657	657	C	134	C	127	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	0	.	p	.	0	E48G	NONSYN	142	144	GAA	494	496	GGA	182;183;186	G;G,A;A	174;176,2;179	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	0	.	p	.	0	F135L	NONSYN	403	405	TTT	755	757	CTT	171;171;172	C;T;T	170;168;170	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	0	.	p	.	0	R143G	NONSYN	427	429	AGA	779	781	GGA	181;177;176	G;G,A;A	177;171,1;169	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	0	.	p	.	0	D171G	NONSYN	511	513	GAT	863	865	GGT	182;182;183	G;G,A;T	178;177,2;166	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	0	.	p	.	0	G189S	NONSYN	565	567	GGC	917	919	AGC	156;157;158	A,G;G;C	147,3;152;154	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	983	983	T	158	T	150	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	1	SNP	p	G120K	0	.	.	358	360	GGT	710	712	GGT	186;186;185	G,A;G,A;T,G,A	180,1;179,1;172,1,1	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	1	SNP	p	A121N	0	.	.	361	363	GCC	713	715	GCC	185;185;186	G;C,A;C	178;180,1;181	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2246	porB1b	1035	1035	95.28	porB1b.l6.c4.ctg.1	1603	139.3	1	SNP	p	A121D	0	.	.	361	363	GCC	713	715	GCC	185;185;186	G;C,A;C	178;180,1;181	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	8190	rpoB	4179	4179	100.0	rpoB.l6.c17.ctg.1	4814	168.9	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1984	1986	AAT	191;191;192	A,C;A;T	183,3;185;186	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	982	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1094	89.4	1	SNP	p	V57M	1	.	.	169	171	ATG	518	520	ATG	170;172;172	A;T;G,T	167;169;168,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
